Compare 10X Genomics Inc (TXG) vs Veritone Inc (VERI) Price & Performance

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.

VERI trades at $1.05, up 2.94% today, but remains in a bearish technical trend with negative earnings and cash flow. The company reported a net loss of $111.73M in 2025, with revenue of $92.19M, and faces multiple securities class action lawsuits. Analyst ratings are split evenly between Buy and Hold, with a minority Sell rating, reflecting uncertainty amid financial challenges and legal overhangs.

The outlook is highly speculative due to persistent losses, negative margins, and legal risks. While the low P/S ratio of 0.87 may attract value hunters, the stock carries significant downside risk from operational cash burn and potential settlement costs. Investors should weigh the speculative potential against substantial financial and litigation headwinds.